Established in Israel to manufacture finished pharmaceutical products
Started chemical synthesis (API production) in Israel
Established topical product operations in Canada
Taro enters the U.S. market with its first FDA-approved topical product.
Established TaroPharma branded division in U.S.
Sun Pharma acquires a controlling interest In Taro
Over $1 Billion Gross Sales (IMS Calendar Year Sales 2012)
Taro re-listed on the NYSE providing improved access to capital markets.